X4 Pharmaceuticals Inc (XFOR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $288.98M
Last updated: Nov 17, 2026 at 4:33 PM ET
X4 Pharmaceuticals Inc (XFOR) Stock Chart
X4 Pharmaceuticals (XFOR) has a latest price of $3.09 on Nov 17, 2026, 36.0% below its 52-week high of $4.83. Its price fell 15.6% over the past 12 months. The month-end price fell 99.9% since Nov 2017, a compound annual decline of 53.4%.
Price Chart
From Nov 2017 to Oct 2026, its highest month-end close was $4,123.50 in Mar 2018 and its lowest $1.68 in Jul 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart XFOR with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for XFOR.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 25.7%, and over 6 months it fell 15.1%. The month-end price fell 86.1% over the 3 years through Oct 2026, a compound annual decline of 48.2%.
| Period | Change |
|---|---|
| 1 month | +12.4% |
| 3 months | -25.7% |
| 6 months | -15.1% |
| 12 months | -15.6% |
| 12 months, with dividends | -15.6% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -86.1% | -48.2% |
| 5 years | -97.7% | -53.0% |
| Since Nov 2017 | -99.9% | -53.4% |
Price by Year
Its best calendar year was 2024, when the price fell 12.5%, and its weakest was 2025, when it fell 81.8%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $3.35 | -16.2% |
| 2025 | $4.00 | -81.8% |
| 2024 | $22.03 | -12.5% |
| 2023 | $25.18 | -15.6% |
| 2022 | $29.82 | -56.6% |
| 2021 | $68.77 | -64.4% |
| 2020 | $193.09 | -39.9% |
| 2019 | $321.32 | -23.1% |
| 2018 | $417.93 | -81.8% |
Trading Range
The price is 0.9% below its 50-day average of $3.12 and 18.0% below its 200-day average of $3.77.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $3.09 | |
| 52-week high | $4.83 | -36.0% |
| 52-week low | $2.43 | +27.2% |
| 50-day average | $3.12 | -0.9% |
| 200-day average | $3.77 | -18.0% |
Price Risk
Over 3 years, its largest fall from a peak was 96.8%.
| Measure | Value |
|---|---|
| 1-year beta | 1.59 |
| Largest fall, 1 year | -47.5% |
| Largest fall, 3 years | -96.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About XFOR
What is XFOR's 1-year price change?
X4 Pharmaceuticals's price fell 15.6% over the past 12 months. With dividends included, the 12-month total return was -15.6%.
What is XFOR's 5-year price change?
X4 Pharmaceuticals's month-end price fell 97.7% over the 5 years through Oct 2026, a compound annual decline of 53.0%. These figures leave out dividends.
What is XFOR's 52-week high and low?
X4 Pharmaceuticals's 52-week high is $4.83 and its 52-week low is $2.43. Its latest price of $3.09 on Nov 17, 2026 is 36.0% below the high.
What is XFOR's beta?
X4 Pharmaceuticals's 1-year beta against the S&P 500 is 1.59, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 47.5%.
Is the XFOR chart free?
Yes. Advanced Charting for XFOR is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
XFOR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors